iolAMD, also known as the “Hubble Implant”, is potentially the greatest breakthrough in the surgical treatment of macular disease in history. It is the world’s first and only micro-incision, injectable, telescopic implant.
iolAMD is a new IOL system for the treatment of early, intermediate and end stage Dry AMD and other macular pathologies including diabetic maculopathy, macular holes, myopic degeneration and hereditary retinal diseases such as Stargardt’s and Best’s.
Invented by leading eye surgeon Dr Bobby Qureshi and optical physicist Professor Pablo Artal, iolAMD represents a huge leap forward in patient safety and optical performance post-operatively.
This ground breaking new procedure is as safe as routine cataract surgery and can be used as an exciting new alternative to monofocal lens implants in appropriate patients with macular disease.
Utilising 2 small incision, hydrophobic acrylic IOLs to produce a Galilean telescope effect, iolAMD can restore central vision in patients suffering from macular disease, greatly improving their quality of life.
iolAMD has achieved regulatory CE approval for Europe. iolAMD is not currently available for sale in the US although preparations for an FDA submission are being made.
iolAMD has been conceived and designed by leading eye surgeons and optical scientists to restore vision to this large group of potential patients.
EL IMPLANTE HUBBLE, PRODUCE UN EFECTO TELESCÓPICO QUE PUEDE AYUDAR A RECUPERAR LA VISIÓN CENTRAL MEJORANDO LA CALIDAD DE VIDA DE LOS PACIENTES CON DEGENERACIÓN MACULAR ASOCIADA A LA EDAD, BEST, MACULOPATÍAS, STARGARDT ETC..
DE MOMENTO NO TENEMOS DATOS DE LOS PRIMEROS PACIENTES A LOS QUE SE LES HA IMPLANTADO ESTE SISTEMA. NO TIENE NADA QUE VER CON LA TERAPIA GÉNICA; ES UNA LUPA PARA LAS PERSONAS QUE NOS LEEN Y NO SON MÉDICOS.
(DOCE DARÁ MÁS INFORMACIÓN CUANDO EL HOSPITAL DE LONDRES NOS LA HAGA LLEGAR)